MarketsandMarkets

ImmunoBio Series 2024 - West Coast Edition

08th - 09th February 2024

DoubleTree by Hilton, San Diego Mission Valley

Bridging Science, Innovation, and Health for a Better Tomorrow

MarketsandMarkets presents the Immunobio Series, an extraordinary trio of conferences taking place on 8-9 February 2024 at DoubleTree by Hilton, San Diego Mission Valley.

MarketsandMarkets 9th Annual Biomarker and Companion Diagnostics Conference: Dive into the world of biomarkers at our flagship event, uniting experts and industry leaders to drive innovation in healthcare, diagnostics, and personalized medicine. Explore groundbreaking research and applications, fostering collaboration and knowledge sharing.

MarketsandMarkets 6th Annual Next Gen Microbiome and Probiotics Conference: Discover the future of microbiome therapies and probiotics. Engage with professionals from diverse sectors to explore microbial innovation, regulatory pathways, and the vital microbiome probiotics connection. Delve into cutting-edge research and strategies for successful commercialization.

MarketsandMarkets Next Gen Immuno-Oncology Conference: Explore the forefront of cancer treatment at our inaugural Immuno-Oncology Conference. Join researchers and industry experts to discuss advancements in ADCs, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors. Participate in discussions, share insights, and shape the future of immuno-oncology.

Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics. Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects. Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation. Clinical Applications of Biomarkers: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches. Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms. Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.
Exploring the Function of the Gut Microbiome and Modulation of Immune Cells Role of human skin microbiome in precision health Modulating the GI Microbiome with Live Biotherapeutic Product to Enhance Efficacy of Cancer Immunotherapy Oral-Systemic Microbiome Connection and its Modulation Modulating the Vaginal Microbiome for Women’s Health and Fertility Mechanisms of Oncobiotic LBP Candidate in Enhancing Cancer Immunotherapy Microbiome as a science and its clinical applications- skin, gut & women’s health Prebiotics, Probiotics and Postbiotics Treating Clostridioides difficile: Microbiota-based Live Biotherapeutic Products to Provide the Answer  Microbiome’s Role in Cancer
Preclinical and Translational Immuno-Oncology Developments Next Gen Antibodies and Targeted Therapies Immune Checkpoint Inhibitors and Combination Therapies Tumor Microenvironment and Cancer Biomarkers CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy Cancer Vaccines and Cancer Microbiome Personalizing Cancer Treatment- Challenges and Opportunities

Join us for this transformative event, where innovation meets collaboration, shaping the future of healthcare and biotechnology. MARKETSANDMARKETS IMMUNOBIO SERIES 2024- SAN DIEGO, CALIFORNIA

CO-LOCATED CONFERENCES

WHAT TO EXPECT

  • CUTTING-EDGE INSIGHTS: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
  • MULTIDISCIPLINARY LEARNING: Gain a comprehensive understanding of microbiome and probiotics research, exploring diverse topics and practical applications across healthcare, biotechnology, and food production.
  • INNOVATIVE IMMUNOTHERAPY: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
  • PROFESSIONAL DEVELOPMENT: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for microbiome and probiotics research.
  • PRACTICAL APPLICATIONS: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
  • PERSONAL AND INDUSTRY GROWTH: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research, microbiome studies, and immunotherapy.

Immerse yourself in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

Steam A - Biomarker and Companion Diagnostics Conference

Stream B - Next Gen Microbiome and Probiotics Conference

Stream C- Next Gen Immuno-Oncology Conference

  1. Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics.
  2. Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects.
  3. Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation.
  4. Clinical Applications of Biomarker: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers
  5. Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches.
  6. Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms.
  7. Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.

 

  1. Exploring the Function of the Gut Microbiome and Modulation of Immune Cells
  2. Role of human skin microbiome in precision health
  3. Modulating the GI Microbiome with Live Biotherapeutic Product to Enhance Efficacy of Cancer Immunotherapy
  4. Oral-Systemic Microbiome Connection and its Modulation
  5. Modulating the Vaginal Microbiome for Women’s Health and Fertility
  6. Mechanisms of Oncobiotic LBP candidate in Enhancing Cancer Immunotherapy
  7. Microbiome as a science and its clinical applications- skin, gut & women’s health
  8. Prebiotics, Probiotics and Postbiotics
  9. Treating Clostridioides difficile: Microbiota-based Live Biotherapeutic Products to Provide the Answer
  10. Microbiome’s role in Cancer

 

  1. Preclinical and Translational Immuno-Oncology Developments
  2. Next Gen Antibodies and Targeted Therapies
  3. Immune Checkpoint Inhibitors and Combination Therapies
  4. Tumor Microenvironment and Cancer Biomarkers
  5. CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
  6. Cancer Vaccines and Cancer Microbiome
  7. Personalizing Cancer Treatment- Challenges and Opportunities

 

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION

Keynote Presentation

09:00 - 09:30

Spatial Analysis in Ulcerative Colitis and Crohn’s Disease

Jiangwei Zhang

Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb

09:30 - 10:00

Opportunities for biomarker development in neuroscience

Pablo Lapuerta

Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.

11:45 - 12:15

The crucial role of biospecimen management in precision medicine

Ayat Alsaraby

Ayat Alsaraby, Sr. Manager, Clinical Biomarker, Repare Therapeutics

12:15 - 12:45

AI and Multimodal Biomarkers for Personalized Pain Medicine

Carl Saab

Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE

Identification of cancer cell surface target for antibody drug conjugate development

Ginette Serrero

Ginette Serrero, Chief Executive Officer, A&G Pharmaceutical, Inc. | Precision Antibody

14:15 - 14:45

Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease

Matteo D’Antonio

Matteo D’Antonio, Assistant Professor, University of California, San Diego

14:45 - 15:15

Why is monitoring predictive biomarker data so difficult for big pharma?

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Patient Identification and Stratification Applying Predictive Models

16:30 - 17:00

Use of Real-World Evidence in discovery of digital biomarkers

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:35

Drinks, Reception & Networking

17:35 - 18:35

Opening Remarks from the Chairperson

 Julius Goepp

Julius Goepp, Founder, CEO, Scaled Microbiomics

08:55 - 09:00

UNVEILING TOMORROW’S HEALTH WITH NEW MICROBIOME FINDINGS

Keynote Presentation

09:00 - 09:30

Interpreting Microbiomes via Multi-Omics in Health, Disease, Aging, and Drug Responses

 Julius Goepp

Julius Goepp, Founder, CEO, Scaled Microbiomics

09:30 - 10:00

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

TBA, Senior Representative, Biolog

TBA, Senior Representative, Biolog

TBA, Senior Representative, Biolog, ,

11:15 - 11:45

TBA, Senior Representative, Bioform Solutions

TBA, Senior Representative, Bioform Solutions

TBA, Senior Representative, Bioform Solutions, ,

11:45 - 12:15

Oral-Systemic Microbiome Connection and its Modulation

 Emily Stein

Emily Stein, CEO, Primal Health Inc.

12:15 - 12:45

Next-Generation Probiotics Against Enteric Pathogen Infection and Chronic Inflammatory Disease

Arun K. Bhunia

Arun K. Bhunia, Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

REVOLUTIONIZING WELLNESS – EXPLORING THE FUTURE OF MICROBIOME AND PROBIOTICS

How Lifestyle and Life Stages affect Gut Microbiota and the power of Biotics.

Miguel Freitas

Miguel Freitas, Vice President - Scientific Affairs, Danone

14:15 - 14:45

Effect of Lactobacillus Johnsonii 456 on Inflammation Caused Diseases, Cardiovascular Disease, Cancer, Diabetes and Obesity

Robert Schiestl

Robert Schiestl, Director and Manager, Microbio Pharma

14:45 - 15:15

Working with live probiotics – insights in developing effective skincare products from formulator’s perspective

Maya Ivanjesku

Maya Ivanjesku, Chief Scientific Officer, M2B Pharma

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Back to Health - An Evolutionary Biology Perspective on the Skin Microbiome

16:30 - 17:00

Modulation of the Aging Gut Microbiome to Improve Health

17:00 - 17:30

Closing Remarks from the Chairperson

 Julius Goepp

Julius Goepp, Founder, CEO, Scaled Microbiomics

17:30 - 17:35

Drinks Reception & Networking

17:35 - 18:35

NEW ANTIBODIES DEVELOPMENT AND TUMOR MICRO-ENVIRONMENT

Identification of potential patient selection biomarkers for the treatment of cancer with tivumecirnon (FLX475) in combination with anti-PD-1

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

09:30 - 10:00

TBA, Senior Representative, Volition

TBA, Senior Representative, Volition

TBA, Senior Representative, Volition, ,

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Case Studies Leveraging 20,000 Digitized IO KM Curves – Interactive Analysis and Real-Time Insights at the Forefront of Immuno-Oncology

Bruno Larvol

Bruno Larvol, Founder & CEO, Larvol

11:15 - 11:45

Recombinant antibodies for Immunotherapy

11:45 - 12:15

Challenges in the clinical development of ADC’s

12:15 - 12:45

Spatial Analytics of the TME and Discovering Spatial Biomarkers for Immunotherapy

Arvind Rao

Arvind Rao, Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

DEVELOPMENTS IN CAR-T AND T-CELL THERAPIES PERSONALIZED IMMUNOTHERAPY

Solution Provider Presentation

14:15 - 14:45

Precision Immunology for targeted therapy

14:45 - 15:15

Role of Cancer Microbiome in IO

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

CAR-T cell therapy in solid tumours

16:30 - 17:00

Panel Discussions

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:35

Drinks Reception & Networking

17:35 - 18:35

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION

Keynote Presentation

09:00 - 09:30

Strategies to optimize CDx in cancer

09:30 - 10:00

Solution Provider Presentation

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Drug and CDx co-development with a therapeutic product

11:15 - 11:45

Solution Provider Presentation

11:45 - 12:15

CDx Launch Success: From Early Biomarker Development to Commercialization

12:15 - 12:45

Building up a successful CDx partnership with Pharma

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES

Leveraging IO markers for companion diagnostics development

14:15 - 14:45

Innovative Safety Biomarker Applications to Drug Development

14:45 - 15:15

Panel Discussion: Biomarker Revolution: Enhancing Patient Care Across Specialties

Nicole Miller

Nicole Miller, Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx

 Julius Goepp

Julius Goepp, Founder, CEO, Scaled Microbiomics

15:15 - 15:45

Closing Remarks from the Chairperson

15:45 - 15:50

END OF CONFERENCE

15:50 - 15:50

Opening Remarks from the Chairperson

 Julius Goepp

Julius Goepp, Founder, CEO, Scaled Microbiomics

08:55 - 09:00

CULTIVATING WELLNESS: PIONEERING THE FUTURE OF MICROBIOME AND PROBIOTICS

Keynote Presentation

Bruce Seal

Bruce Seal, Instructor, Biology, Oregon State University

09:00 - 09:30

Effective Microbiome Therapeutics in Production

09:30 - 10:00

Genetic Methods to Improve Lyophilization Survival in Bacteroides

Kevin Roelofs

Kevin Roelofs, Principal Consultant, Greenbeard Consulting LLC

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Restoring Nitric Oxide: Prebiotic Nitrate and the Oral Microbiome

Shawn Green

Shawn Green, Founder, MyFitStrip

11:15 - 11:45

Probiotics from Idea to Shelf: Bringing a New Strain to Market

Zachery Lewis

Zachery Lewis, Probiotic/Prebiotic/Microbiome Expert,

11:45 - 12:15

Fiber Interventions and Cancer and Microbiome Kathrine Whiteson, Associate Professor, Molecular Biology and Biochemistry School of Biological Sciences, University of California Irvine

12:15 - 12:45

Probiotics from Plants and its Key Benefits

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

EXPLORING THE INTERPLAY OF DIET, ANTIBODIES, AND IMMUNOTHERAPEUTIC STRATEGIES

Fine-Tuned Prebiotic Fiber Structures to Effective Support Probiotic-Type Bacteria

14:15 - 14:45

The Impact of Diet and Antibiotics on Colorectal Cancer and Immunotherapy

14:45 - 15:15

Panel Discussion

15:15 - 15:45

Closing Remarks from the Chairperson

 Julius Goepp

Julius Goepp, Founder, CEO, Scaled Microbiomics

15:45 - 15:50

END OF CONFERENCE

15:50 - 15:50

Keynote Presentation

09:00 - 09:30

PRECLINICAL AND TRANSLATIONAL IMMUNO-ONCOLOGY UPDATES- NEW CHECKPOINTS FOR IO

Pre-clinical models for Immune checkpoint modulators

09:30 - 10:00

Solution Provider Presentation

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Translational approach in developing right IO therapy

11:15 - 11:45

Solution Provider Presentation

11:45 - 12:15

Development of new generation DNA vaccines

12:15 - 12:45

Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

CANCER MICROBIOME AND IMMUNOTHERAPY: PARTNERS IN PERSONALIZED CANCER CARE

Future opportunities in clinical development of ICI’s

14:15 - 14:45

The Intersection of Immunology and Oncology: Advancing Targeted Therapy Paradigms

14:45 - 15:15

Panel Discussion

Paul (Weibing) Shi

Paul (Weibing) Shi, Principal Scientist, NGS & Infrastructure Lead, Amgen

15:15 - 15:45

Closing Remarks from the Chairperson

15:45 - 15:50

END OF CONFERENCE

15:50 - 15:50

SPEAKERS

John Rossi

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Sahil Khanna

Sahil Khanna

Professor of Medicine, Chair GI Hospital Practice, Associate Program Director Internal Medicine Residency Program, Medical Director Desk and Secretarial Operations, Mayo Clinic

Shawn Green

Shawn Green

Founder, MyFitStrip

John Kirby

John Kirby

Chair of Microbiology & Immunology at MCW | Co-Founder, Rose Biosciences

Zachery Lewis

Zachery Lewis

Probiotic/Prebiotic/Microbiome Expert,

TBA, Senior Representative, Biolog

TBA, Senior Representative, Biolog

,

TBA, Senior Representative, Bioform Solutions

TBA, Senior Representative, Bioform Solutions

,

Antonio Gomes

Antonio Gomes

Principal Scientist, Xbiome

Christopher Damman

Christopher Damman

Senior Medical & Scientific Advisory Board Member, BCD Bioscience

TBA, Senior Representative, Helaina

TBA, Senior Representative, Helaina

,

Tariq Warsi

Tariq Warsi

Vice President, Novome Biotechnologies

Robert Schiestl

Robert Schiestl

Director and Manager, Microbio Pharma

Bruce Seal

Bruce Seal

Instructor, Biology, Oregon State University

Marina Santiago

Marina Santiago

Director of Research and Development, FitBiomics

TBA, Senior Representative, Sanyou Bio

TBA, Senior Representative, Sanyou Bio

,

TBA, Senior Representative, TransCure Services

TBA, Senior Representative, TransCure Services

,

TBA, Senior Representative, Veracyte

TBA, Senior Representative, Veracyte

,

TBA, Senior Representative, Biocytogen

TBA, Senior Representative, Biocytogen

,

TBA, Senior Representative, Volition

TBA, Senior Representative, Volition

,

Bruno Larvol

Bruno Larvol

Founder & CEO, Larvol

Arvind Rao

Arvind Rao

Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor

 Paul Kassner

Paul Kassner

Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

Jack SH Chen

Jack SH Chen

Scientific Director, Immuno-Oncology, Precision Medicine, AbbVie

Daud Adil

Daud Adil

Director, Melanoma Program, UCSF Medical Center

Collin

Collin

Scientist, EpigenDx

Matt Giacalone

Matt Giacalone

CEO, Vaxiion Therapeutics

Nur Hasan

Nur Hasan

Chief Executive Officer, EzBiome Inc

Kareem Barghouti

Kareem Barghouti

Co-Founder, VastBiome

Paul (Weibing) Shi

Paul (Weibing) Shi

Principal Scientist, NGS & Infrastructure Lead, Amgen

Charles Joel Rosser

Charles Joel Rosser

Medical Director, Cedars-Sinai

Jiangwei Zhang

Jiangwei Zhang

Senior Principal Scientist, Bristol Myers Squibb

Ranjan Perera

Ranjan Perera

Associate Professor, Johns Hopkins University

Carl Saab

Carl Saab

Professor, Innovation Lead Digital Health, Cleveland Clinic

Nicole Miller

Nicole Miller

Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx

Jakob Dupont

Jakob Dupont

Executive Partner, Sofinnova Ventures

Pablo Lapuerta

Pablo Lapuerta

Chief Executive Officer, 4M Therapeutics Inc.

Matteo D’Antonio

Matteo D’Antonio

Assistant Professor, University of California, San Diego

 Julius Goepp

Julius Goepp

Founder, CEO, Scaled Microbiomics

Ayat Alsaraby

Ayat Alsaraby

Sr. Manager, Clinical Biomarker, Repare Therapeutics

Miguel Freitas

Miguel Freitas

Vice President - Scientific Affairs, Danone

Vandana Sharma

Vandana Sharma

Principal Nutrition Scientist, Pharmavite

Larry Weiss

Larry Weiss

CEO and Founder, Symbiome

Maya Ivanjesku

Maya Ivanjesku

Chief Scientific Officer, M2B Pharma

Arun K. Bhunia

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

 Emily Stein

Emily Stein

CEO, Primal Health Inc.

 Lada Rasochova

Lada Rasochova

CEO, Dermala

Kathrine Whiteson

Kathrine Whiteson

Associate Professor, Molecular Biology and Biochemistry School of Biological Sciences, University of California Irvine

Ginette Serrero

Ginette Serrero

Chief Executive Officer, A&G Pharmaceutical, Inc. | Precision Antibody

ENQUIRE NOW

LOCATION

Venue

DoubleTree by Hilton, San Diego Mission Valley

PAST EVENT GALLERY